Clinical trials: Umbilical Cord
Knee Osteoarthritis
Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis
This clinical trial is performed with patients with knee osteoarthritis who were radiologically diagnosed with Kellgren-Lawrence (K\&L) grade 2 or 3.
- Trial name
- NCT04037345
- Testing
- SMUP-IA-01(low-dose), SMUP-IA-01(mid-dose), SMUP-IA-01(high-dose)
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Medipost Co Ltd.
Androgenic Alopecia
Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
The purpose of this study is to assess whether cosmetic investigational product containing NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.
- Trial name
- NCT03676400
- Testing
- conditioned media of umbilical cord blood-derived stem cells
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Medipost Co Ltd.
Cartilage Injury, Osteoarthritis
Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury
The purpose of the study is to assess and compare the safety and efficacy of the allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product (Cartistem®) to that of a microfracture treatment in patients with…
- Trial name
- NCT01041001
- Testing
- Cartistem, Microfracture treatment
- Where
- 8 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Medipost Co Ltd.
Trapeziometacarpal Osteoarthritis
Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of Trapeziometacarpal Osteoarthritis
The objective of this clinical trial is to evaluate whether a human umbilical cord amniotic membrane allograft can serve as an interposition implant in the surgical treatment of trapeziometacarpal osteoarthritis.
- Trial name
- NCT07435571
- Testing
- with SclerFIX
- Where
- 4 sites in France
- Volunteers
- 22 people
- Sponsor
- TBF Genie Tissulaire
Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
The purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with ProHema.
- Trial name
- NCT00890500
- Testing
- Fludarabine, Melphalan, Antithymocyte Globulin
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fate Therapeutics
Covid19, Prophylaxis
Mesenchymal Stem Cells for the Treatment of COVID-19
This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the…
- Trial name
- NCT04573270
- Testing
- PrimePro
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
Hereditary Ataxia
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements.
- Trial name
- NCT01360164
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Alzheimer's Disease
Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease
This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived…
- Trial name
- NCT02054208
- Testing
- human umbilical cord blood derived mesenchymal stem cells, Normal saline 2mL
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Medipost Co Ltd.
Diabetic Nephropathy Type 2
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65…
- Trial name
- NCT07396155
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Cerebral Infarction
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects
- Trial name
- NCT02378974
- Testing
- Cordstem-ST
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CHABiotech CO., Ltd
Cerebral Infarction
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.
- Trial name
- NCT03176498
- Testing
- Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Chronic Back Pain, Degenerative Disc Disease Lumbar
CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.
- Trial name
- ADAPT (NCT07137559)
- Testing
- CELZ-201-DDT
- Sponsor
- Creative Medical Technology Holdings Inc
Osteoarthritis, Knee
Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury
In terms of the surgical treatment of the cartilage injury, various techniques and ways are created to repair or regenerate articular surface of synovial joint following traumatic damage or degeneration of the cartilage.
- Trial name
- NCT05016011
- Testing
- Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs), Marrow cellution
- Where
- Malaysia
- Volunteers
- 28 people
- Sponsor
- Cytopeutics Sdn. Bhd.
Keloid
Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid
The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020.
- Trial name
- Keloid (NCT04326959)
- Testing
- Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium, Conditioned Medium, Triamcinolone Acetonide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PT. Prodia Stem Cell Indonesia
Premature Ovarian Failure
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
Evaluate the safety of human umbilical cord mesenchymal stem cells (hucMSCs) in POI treatment; Evaluate the effective hucMSCs in POI treatment.
- Trial name
- NCT03816852
- Testing
- hucMSCs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Inherited Metabolic Disorders (IMD)
A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456
A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456
- Trial name
- IMD-002 (NCT04008849)
- Testing
- Safety and efficacy assessments
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Magenta Therapeutics, Inc.
Hematologic Malignancies
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity…
- Trial name
- NCT01627314
- Testing
- ProHema-CB, Untreated CB
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Fate Therapeutics
Acute Stroke
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
This study is a first-in-human assessment of safety of using umbilical cord mesenchymal stem cells (UCMSCs) in patients with Acute Ischemic Stroke via a combination of intra arterial (IA) and intravenous (IV) stem cell…
- Trial name
- NCT04434768
- Testing
- UMSC01
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Multiple Sclerosis
Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (MS) patients.
- Trial name
- NCT02034188
- Testing
- Umbilical cord mesenchymal stem cells
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Translational Biosciences
Bronchopulmonary Dysplasia
Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in…
- Trial name
- EVENEW (NCT06279741)
- Testing
- Endotracheopulmonary Instillation, Suspension
- Where
- 8 sites in Belgium, Italy
- Volunteers
- 265 people
- Sponsor
- EXO Biologics S.A.